Pacira, a publicly traded pharmaceutical company focused on advancing non-opioid therapies to improve patient outcomes, will deploy GEP’s AI-native spend analysis software to gain insight into its indirect spend, identify savings opportunities, and support procurement decisions and financial outcomes.
Founded in 2006, Pacira operates across key locations in the United States and internationally, with its innovative non-opioid therapies addressing pain management. The company, with more than $725M in revenue, has helped treat more than 18 million patients globally.
By adopting GEP’s spend analysis capabilities, Pacira will improve spend transparency, strengthen financial control, and identify new opportunities to drive value across the enterprise.